Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRγ–Syk–Card9–dependent innate immune activation by Werninghaus, Kerstin et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
The Rockefeller University Press  $30.00
J. Exp. Med. Vol. 206 No. 1  89-97
www.jem.org/cgi/doi/10.1084/jem.20081445
89
BRIEF DEFINITIVE REPORT
        Tuberculosis causes 2 million deaths per year 
and is increasingly diffi   cult to treat because of 
multiple drug resistance. In addition, the exist-
ing live vaccine,   Mycobacterium bovis   BCG, lacks 
effi   cacy in most developing countries where the 
major burden of disease occurs (  1  ). This failure 
has been attributed to exposure to environmental 
mycobacteria that induces low-level antimyco-
bacterial immunity and blocks the BCG vaccine 
  “  take  ”   (  2  ). The development of recombinant 
  Mycobacterium tuberculosis   (MTB) antigens as sub-
unit vaccines is an attractive strategy, because 
they are not aff  ected by prior exposure to my-
cobacteria and, in contrast to BCG, are safe in 
immunocompromised persons. However, elic-
itation of protective immunity to intracellular 
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  Novel vaccination strategies against   Mycobacterium tuberculosis   (MTB) are urgently 
needed. The use of recombinant MTB antigens as subunit vaccines is a promising approach, 
but requires adjuvants that activate antigen-presenting cells (APCs) for elicitation of 
protective immunity. The mycobacterial cord factor Trehalose-6,6-dimycolate (TDM) and its 
synthetic analogue Trehalose-6,6-dibehenate (TDB) are effective adjuvants in combination 
with MTB subunit vaccine candidates in mice. However, it is unknown which signaling 
pathways they engage in APCs and how these pathways are coupled to the adaptive im-
mune response. Here, we demonstrate that these glycolipids activate macrophages and 
dendritic cells (DCs) via Syk  –  Card9  –  Bcl10  –  Malt1 signaling to induce a specifi  c innate 
activation program distinct from the response to Toll-like receptor (TLR) ligands. APC 
activation by TDB and TDM was independent of the C-type lectin receptor Dectin-1, but 
required the immunoreceptor tyrosine-based activation motif  –  bearing adaptor protein Fc 
receptor      chain (FcR    ). In vivo, TDB and TDM adjuvant activity induced robust combined 
T helper (Th)-1 and Th-17 T cell responses to a MTB subunit vaccine and partial protection 
against MTB challenge in a Card9-dependent manner. These data provide a molecular basis 
for the immunostimulatory activity of TDB and TDM and identify the Syk  –  Card9 pathway 
as a rational target for vaccine development against tuberculosis. 
© 2009 Werninghaus et al.  This article is distributed under the terms of an At-
tribution–Noncommercial–Share Alike–No Mirror Sites license for the fi  rst six 
months after the publication date (see http://www.jem.org/misc/terms.shtml). 
After six months it is available under a Creative Commons License (Attribution–
Noncommercial–Share Alike 3.0 Unported license, as described at http://creative-
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  Here, we report that the mycobacteria-derived glyco-
lipid TDM and the synthetic adjuvant analogue TDB selec-
tively activate the FcR      –  Syk  –  Card9 pathway in APC to 
induce a unique innate immune activation program that di-
rects protective Th-1 and -17 immunity after subunit MTB 
vaccination. 
    RESULTS AND DISCUSSION   
  Priming of IFN-     and IL-17 production by the adjuvant TDB 
  To characterize the adjuvant activity of TDB, we fi  rst immu-
nized mice with H1 together with TDB or the TLR9 ligand 
CpG oligodeoxynucleotide (ODN) 1826, and investigated 
the priming of Th-1 and -17 T cell responses by restimulating 
lymph node cells with H1 in vitro. Both TDB and CpG in-
duced a robust Th-1 T cell response characterized by profound 
antigen-specifi  c IFN-     production (  Fig. 1 A  ).   However, only 
TDB, and not CpG, also activated a strong H1-specifi  c Th-
17 T cell response, indicating that this glycolipid has an adju-
vant activity that diff  ers fundamentally from that of a classical 
TLR agonist (  Fig. 1 A  ). Because the immunostimulatory ca-
pacity of TDB presumably depends on direct eff  ects on the 
innate immune system, we next analyzed the ability of TDB 
to activate APCs in vitro. 
  TDB and TDM trigger distinct APC activation programs 
  As an initial readout for cell activation, we used nitric oxide 
(NO) production from BM-derived macrophages (BMMs; 
  Fig. 1 B  ). TDB, as well as the cord factor TDM, induced 
substantial amounts of NO, especially after priming with 
IFN-     (  Fig. 1 B  ). However, compared with CpG, the kinet-
ics of TDB-mediated NO production was delayed (  Fig. 1 C  ). 
To investigate the diff  erences in the eff  ects of TDB and CpG 
on myeloid cell activation more generally, we next measured 
global changes in gene expression over time. As expected, 
both stimuli induced substantial transcriptional reprogram-
ming, again with an overall slower response to TDB (  Fig. 1 D  ). 
We also observed qualitative diff  erences in gene expression, 
as a hierarchical clustering revealed TDB-selective (cluster C) 
or CpG-selective gene induction (cluster D) in addition to 
common down- and up-regulated target genes (cluster A, B1) 
and genes induced early by CpG and later by TDB (cluster 
B2). Selected examples of TDB-induced genes were con-
fi  rmed at the protein level, validating the microarray data 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20081445/DC1). We then focused on diff  erentially ex-
pressed cytokines that can direct Th cell diff  erentiation (  Fig. 1, 
E  –  G  ). IL-12p40 was strongly induced by CpG but not by 
TDB (  Fig. 1 E  ), whereas IL-6 and IL-1     were expressed tran-
siently after CpG and delayed after TDB treatment (  Fig. 1, 
F and G  ). Notably, TDB, but not CpG, triggered a signifi  cant 
release of IL-1     into the culture supernatant (  Fig. 1 F  ). We 
also analyzed the ability of TDB to activate DCs as the most 
potent APC. We found that TDB caused up-regulation of 
MHC-II and of the costimulatory molecules CD40, CD80, 
and CD86 on the cell surface (  Fig. 1 H  ) and triggered cyto-
kine and NO release in DCs in a manner similar to that in 
pathogens with recombinant subunit vaccines has not been 
straightforward. 
  During infection, or vaccination with BCG, the innate 
immune system recognizes so-called pathogen-associated mo-
lecular patterns (PAMPs), resulting in the activation of APCs. 
PAMPs derived from diff  erent classes of pathogens bind to 
diverse families of pattern recognition receptors that include 
Toll-like receptors (TLRs), C-type lectins, or NOD-like re-
ceptors. These interactions decode pathogen information by 
triggering distinct signaling pathways to diff  erentially activate 
APCs, thereby directing the adaptive eff  ector response in a 
manner that is specifi  cally tailored to the invading microbe. 
Ligands for TLRs, such as bacterial CpG DNA or LPS, ac-
tivate signaling via the adaptor protein Myd88 and induce T 
helper (Th)-1  –  directing cytokines like IL-12 (  3  ). In contrast, 
the binding of the     -glucans Curdlan or Zymosan to the C-
type lectin receptor Dectin-1 activates the kinase Syk, initiat-
ing signaling via the Card9  –  Bcl10  –  Malt1 pathway, and it can 
direct Th-17 diff  erentiation (  4, 5  ). Other immunoreceptor ty-
rosine-based activation motif (ITAM)  –  coupling receptors can 
trigger Syk  –  Card9 activation in myeloid cells via the adaptor 
proteins Dap12 or Fc receptor      chain (FcR    ) (  6  ), but their 
eff  ects on adaptive immune responses are not known. 
  Protection against MTB infection requires antigen-spe-
cifi  c CD4  +   Th-1 T lymphocytes producing IFN-    , which 
enables macrophages to kill intracellular mycobacteria (  7  ). 
The induction of IL-17  –  producing Th-17 cells after immuni-
zation was recently shown to contribute to protection by 
rapid recruitment of eff  ector cells, including Th-1 cells, to the 
site of infection (  8  ). 
  Because recombinant protein antigens usually do not acti-
vate APCs, for successful use as subunit vaccines the addition 
of adjuvants is necessary. The adjuvant most widely used in 
humans is aluminum hydroxide, which induces antibody re-
sponses but only ineffi   ciently primes T cell responses required 
for control of intracellular infections. CFA, an emulsion made 
of killed MTB, effi   ciently induces Th-1 responses in mice, 
but is too toxic for use in humans. In the search for adjuvants 
that are both safe and eff  ective, purifi  ed PAMPs and their 
synthetic analogues have been investigated. The mycobacte-
rial cell wall component Trehalose-6,6-dimycolate (TDM), 
also known as cord factor, has potent infl  ammatory activity 
(  9  ) and is used alone or in combination with a TLR4 ligand 
as an experimental adjuvant (  8, 10  ). The less toxic, synthetic 
cord factor analogue Trehalose-6,6-dibehenate (TDB; for 
structures see Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20081445/DC1) (  11  ) induces robust Th-1 
immunity after vaccination with the recombinant MTB an-
tigen H1, conferring protection to infection challenge with 
a reduction in mycobacterial load comparable to the   “  gold 
standard  ”   BCG (  12, 13  ). H1 is a fusion of the MTB proteins 
Ag85B and ESAT-6 that is currently being tested as a subunit 
vaccine candidate in humans (  1  ). However, the mechanism(s) 
by which the glycolipid adjuvants TDB and TDM initiate 
protective T cell immunity, particularly how they activate 
APCs, are unknown. JEM VOL. 206, January 19, 2009  91
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    Figure 1.         Th1/Th17 induction by TDB correlates with a distinct APC activation program.   (A) C57BL/6 mice were s.c. immunized twice with H1 
antigen mixed with CpG (CpG) or DDA-TDB (TDB) or left untreated (control). 2 wk after the last injection, draining lymph node cells were restimulated 
with 10   μ  g/ml H1 antigen for 96 h, followed by detection of IFN-     and IL-17. Mean and SD (  n   = 3  –  4 mice) from representative experiment out of three 
are shown. (B) BMMs were stimulated for 96 h in triplicate with 100 ng/ml LPS, 1   μ  M CpG ODN, and TDB, with or without prestimulation with 20 ng/ml 
IFN-    . NO production measured as nitrites by Griess assay. (right) TDB and TDM concentration of 20   μ  g/ml. Mean and SD of triplicate wells. (C) Stimula-
tion of IFN-      –  primed BMMs as indicated. (D) Gene expression changes induced by TDB and CpG in IFN-      –  primed BMMs. (top) Number of probe sets up-
regulated by   >  10-fold. (bottom) Hierarchical cluster analysis of z-score  –  normalized expression of regulated probe sets (Max-Min > 200,  Max/Min > 10). 
Yellow indicates high, blue indicates low relative expression. (E  –  G) Cytokine mRNA and ELISA protein data.   Il12b   averages of probe sets 1449497_at and 
1419530_at;   Il1b   probe set 1449399_a_at;   Il6   probe set 1450297_at. ELISA data are from triplicate wells. (H) Up-regulation of CD80, CD86, CD40, and 
MHC-II on DCs after stimulation with 30   μ  g/ml TDB (48 h; red line) or 100 ng/ml LPS (24 h; black line) compared with unstimulated cells (gray shade) as 
determined by FACS analysis. Representative of two experiments.     92 MECHANISM OF THE GLYCOLIPID ADJUVANTS TDB AND TDM   | Werninghaus et al. 
produce IL-6 and -1     (Fig. S5). As the small molecule Syk 
inhibitor Piceatannol blocked NO release induced by TDB 
and TDM from BMMs in a dose-dependent fashion (  Fig. 2 C   
and Fig. S6), the enzymatic function of Syk is essential for 
the Myd88-independent innate immune cell activation in re-
sponse to these glycolipids in vitro  .   Interestingly, Geisel et al. 
reported that Myd88 is required for cord factor  –  induced in-
fl  ammation in vivo (  9  ). Further, we have recently found that 
Myd88 is required for the Th1-directing adjuvant eff  ect of 
TDB in vivo (  15  ). Because TLR2, TLR3, TLR4, and TLR7 
were not required (  15  ), the phenotype of Myd88 knockout 
mice in vivo may indicate a defect in the glycolipid-induced 
eff  ector phase, e.g., downstream of the IL-1 receptor. 
  Syk can use the myeloid cell –  specifi  c adaptor protein Card9 
for the activation of macrophages or DCs in response to vari-
ous signals (  4  –  6  ). We therefore used Card9      /      BMMs to test 
whether APC activation by TDB requires this adaptor pro-
tein. Similar to Syk      /      BMMs, cells lacking Card9 failed to 
produce NO in response to TDB (Fig. S7, available at http://
www.jem.org/cgi/content/full/jem.20081445/DC1) and to 
up-regulate expression of iNOS, IL-6, or IL-1    , whereas the 
CpG-mediated expression of these molecules was largely un-
aff  ected (  Fig. 3 A  ).   Gene expression profi  ling was used to 
determine whether Card9 is required for all transcriptional 
responses to TDB stimulation (  Fig. 3 B  ). The     -glucan Cur-
dlan, which is a ligand of the C-type lectin receptor Dectin-1 
that is known to signal via Card9 (  5  ), and TDB induced very 
similar genome-wide transcriptional responses that were dis-
tinct from the pattern of CpG-induced activation. In the ab-
sence of Card9, responses to TDB and Curdlan were almost 
completely abrogated, whereas CpG-triggered gene expres-
sion was unaff  ected. To further study the function of Card9 
in TDB-induced APC activation, we also analyzed DCs and 
found that the release of IL-1    , IL-6, and TNF-    , as well 
as nuclear translocation of the transcription factor NF-    B, 
was triggered by TDB in a strictly Card9-dependent manner 
(Fig. S8 and Fig. S9). In contrast to BMMs (  Fig. 1 E  ), DCs 
also produced IL-12p40 after stimulation with TDB or Cur-
dlan, as well as IL-12p70 and -23, which are all dependent on 
Card9 (  Fig. 3 C  ). Notably, LPS was a far stronger inducer of 
these Th diff  erentiation factors than TDB (  Fig. 3 C  ). Curdlan 
was comparably weak in IL-12 induction, in agreement with 
a previous study (  5  ). It is known that Card9 can couple to the 
downstream adaptor and scaff  old proteins Bcl10 and Malt1 
(  4  ). Using TNF-     production by DCs as readout for Bcl10 
and Malt1 signaling, we found an additional requirement for 
these molecules in the response to TDB and TDM (  Fig. 3 D  ). 
Thus, these experiments demonstrate on a genetic and tran-
scriptional level that TDB and TDM engage a specifi  c innate 
pathway that depends on Syk kinase activity and the adaptor 
proteins Card9, Bcl10, and Malt1. 
  TDB/TDM activate APCs independent of Dectin-1, 
yet require the ITAM-bearing adaptor protein FcR     
  As the     -glucan receptor Dectin-1 has already been im-
plicated in APC responses to whole mycobacteria (  16  –  18  ), 
BMMs (Fig. S3). Thus, the adjuvant TDB potently activates 
APCs, in which it triggered a diff  erent expression program 
compared with TLR stimulation and presumably activates a 
distinct intracellular signaling pathway. 
  Requirement for Syk and Card9 in TDB-/TDM-induced 
APC activation 
  Diverse pattern recognition receptor families use diff  erent 
proximal signaling proteins to mediate myeloid cell acti-
vation. Whereas most TLRs signal via the adaptor protein 
MyD88 (  3  ), certain ITAM receptors or ITAM-coupled 
receptors like C-type lectins use the kinase Syk for down-
stream signaling (  14  ). To study whether any of these path-
ways are required for TDB-mediated cell activation we used 
MyD88      /      and Syk      /      BMMs (  Fig. 2, A and B  ).   As ex-
pected, control stimulation with TLR agonists resulted in 
normal production of NO in Syk      /      cells, but was ineff  ective 
in MyD88      /      BMMs. In contrast, TDB and TDM induced 
NO production in MyD88      /      cells to a similar extent as in 
wild-type cells, but did not stimulate NO synthesis in the ab-
sence of Syk. Furthermore, the TDB-stimulated expression 
and production of IL-6 by Myd88      /      BMMs was largely in-
tact (Fig. S4, available at http://www.jem.org/cgi/content/
full/jem.20081445/DC1), whereas Syk      /      BMMs failed to 
    Figure 2.         TDB-/TDM-induced APC activation is independent of 
Myd88, yet requires Syk activity.   (A and B) Wild-type, Myd88     /   ,  and 
Syk     /     BMMs primed with IFN-     were stimulated for 60 h (A) and 96 h 
(B) before NO release was measured. TDB and TDM were used at 20   μ  g/ml 
in suspension (A and B) and coated onto tissue culture plastic in titrations 
ranging from 4   μ  g/ml to 15 ng/ml (A). Mean and SD of triplicate wells. 
Experiments were repeated three times with similar results. (C) TDB-in-
duced macrophage activation is sensitive to Piceatannol. IFN-    – primed 
BMMs were pretreated for 30 min with increasing doses of Piceatannol 
before stimulation with TDB (5 or 20   μ  g/ml) or LPS (100 ng/ml). Mean and 
SD of triplicate wells. Representative of two experiments.     JEM VOL. 206, January 19, 2009  93
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macrophage activation. In contrast to Dectin-1, which pos-
sesses an ITAM-like motif in its cytoplasmic region, a large 
number of Syk-activating myeloid cell receptors are as-
sociated with one of the ITAM-bearing adaptor proteins 
Dap12 or FcR     (encoded by the   Fcer1g   gene). To gain fur-
ther insight into the signaling requirements of APC activa-
tion by TDB and TDM, we used Dap12      /      and Fcer1g      /      
BMMs (  Fig. 3, F and G  ). Expression of Nos2 was indepen-
dent of Dap12 in response to TLR ligands, Curdlan, and 
TDB/TDM. In contrast, in Fcer1g      /     , BMM expression 
we tested its role in recognition of the mycobacterial cord 
factor TDM or TDB by APC. Using IFN-      –  primed Dec-
tin-1      /      BMMs, we found the expected defect in NO pro-
duction after stimulation with Curdlan, but the response to 
TDB and TDM, as well as to the TLR stimuli CpG and 
LPS, was not aff  ected (  Fig. 3 E  ). In addition, the expression 
of Nos2 and IL-1     after stimulation with TDB, TDM, and 
LPS was independent of Dectin-1 (Fig. S10, available at 
http://www.jem.org/cgi/content/full/jem.20081445/DC1). 
Thus, Dectin-1 is not required for TDB-/TDM-induced 
    Figure 3.         TDB/TDM activate APCs via Card9  –  Bcl10  –  Malt1.   (A) BMM were stimulated with 1   μ  M CpG or 40   μ  g/ml TDB for 72 h. Expression of iNOS, 
IL-1    , and IL-6 was determined by qRT-PCR. Mean and SD of quadruplicate wells, representative of three independent experiments. (B) Expression profi  l-
ing of wild-type and Card9     /     IFN-     –  primed BMMs 48 h after stimulation with CpG, TDB, or Curdlan. Hierarchical clustering of 606 probe sets with regu-
lated expression (Max/Min   >   5, Max-Min   >   100). Yellow indicates high expression, blue indicates low relative expression. The genotype of BMMs is 
indicated with + (wild type) and   –   (Card9     /    ). (C) Card9 dependence of TDB-induced production of IL-12p40, IL-23, and IL-12p70 from DCs. LPS and Cur-
dlan were included as controls. Shown are mean and SD of triplicate cultures, harvested 72 h after stimulation. (D) Lack of TNF-     production from DCs 
defi  cient in Bcl10 or Malt1. Mean and SD, repeated twice. (E) IFN-    – primed  BMMs  from  Dectin-1    /   ,  Card9    /    , and C57BL/6 mice were stimulated in 
triplicates for 72 h, as described in   Fig. 2 A  , before measurement of nitrites using the Griess assay. Mean and SD of representative experiment from two 
performed. (F) Expression of Nos2 mRNA in IFN-      –  primed BMMs from C57BL/6, Dap12     /    , and Fcer1g     /     mice 48 h after stimulation as indicated. Fold 
change relative to medium control. Mean and SD of quadruplicate determinations, representative of at least two experiments. (G) NO production by 
C57BL/6 and Fcer1g     /     IFN-     –  primed BMMs 72 h after stimulation as indicated. Mean and SD of triplicate wells. Representative of three experiments.     94 MECHANISM OF THE GLYCOLIPID ADJUVANTS TDB AND TDM   | Werninghaus et al. 
for linking TDB and TDM recognition to the Syk  –  Card9 
signaling pathway. 
  Lack of TDB-/TDM adjuvant activity in Card9      /      mice 
  The Syk  –  Card9 pathway is a pattern recognition pathway that 
can couple to adaptive immunity (  5  ). To investigate whether 
of Nos2 and production of NO were specifi  cally abrogated 
after stimulation with TDB or TDM, whereas TLR-trig-
gered and Dectin-1  –  induced activation was intact. The 
specifi  c requirement for FcR    , but not Dap12, was also 
found for TDB-/TDM-induced expression of IL-6 (Fig. 
S11). Therefore, the ITAM-bearing adaptor FcR     is critical 
    Figure 4.         Induction of protective immunity to tuberculosis by TDB/TDM adjuvant requires Card9.   (A) Wild-type and Card9     /     mice were immu-
nized via hind footpad injection on day 0 and 20 (arrows) with H1 in DDA or DDA/TDB liposomes. Mean and SD of the increase in footpad thickness is 
shown (footpad number,   n   = 12). Signifi  cantly different for comparison of wild-type and Card9     /     after DDA/TDB injection at all time points (P   <   0.01). 
Representative of two independent experiments. (B) Number of cells in draining lymph nodes 2 wk after the 2 injections. Data are from two independent 
experiments (  n   = 3  –  5 for each data point). (C) Production of IFN-     and IL-17 by draining lymph node cells after restimulation with H1 protein. Mean and 
SD (  n   = 4), two experiments with similar results. (D) IgG2a levels in sera of mice injected three times. Control, untreated mice; D, DDA;   D/T:   DDA/TDB;  WT, 
wild type. (E) Mice injected three times, or naive mice, were infected by aerosol with 100 CFU MTB. After 6 wk, mice were killed and the bacterial load was 
determined in the lung. (left) Wild-type mice; (right) Card9     /     mice. Shown are mean and SD from six mice per group, except for unvaccinated Card9     /    
mice, where two mice died before day 42. (F) Frequency analysis of CD4 T cells producing IL-17 (left) or IFN-     (right) from mediastinal lymph nodes 6 wk 
after MTB infection. Asterisks indicate signifi  cant differences (*, P   <   0.05; **, P   <   0.01; ***, P   <   0.001).     JEM VOL. 206, January 19, 2009  95
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TDM remain(s) to be determined. As we have excluded an 
essential role of Dectin-1, its contribution to the activation of 
APCs by whole mycobacteria (  16  –  18  ) is likely caused by my-
cobacterial ligands distinct from TDM. Given the multitude 
of receptors that can activate Syk  –  Card9 in myeloid cells, our 
fi   nding that the ITAM-bearing adaptor FcR    , but not 
Dap12, is essential for activation of macrophages by TDB and 
TDM provides a starting point for the isolation of pattern 
recognition receptors for these mycobacterial glycolipids. Al-
though Dap12-coupled molecules like TREMs, Sirpb, and 
PILR-b are unlikely to be involved, some C-type lectins 
(e.g., Mincle, Dectin-2, and DCAR), as well as other FcR    -
coupled proteins (e.g., OSCAR and PIRA), can be consid-
ered candidate receptors. 
  Our results further indicate that TDB and TDM constitute 
adjuvants with a now molecularly defi  ned mode of action that 
is distinct from TLR-triggering adjuvants engaging Myd88 
(CpG and IC31) (  20  –  22  ) or Trif (Monophosphoryl Lipid A) 
(  23  ). It is intriguing that the innate activation program induced 
by the mycobacterial cord factor and its analogue TDB in-
structs the development of the appropriate, protective Th-1 
and -17 response. Consistent with recent fi  ndings that estab-
lished the importance of Th-17 cells after subunit vaccination 
using a TDM-containing adjuvant (  8  ), the degree of Th-17 
cell induction correlated with protection to MTB-challenge in 
our experiments. According to the current concept of murine 
and human Th-17 diff  erentiation (  24, 25  ), TDB likely oper-
ates through the combined induction of IL-1    , -6, and -23 
from APCs, whereas CpG may inhibit Th-17 diff  erentiation 
through IL-12 and IFN-     (  5, 25  ). Our fi  nding that the glyco-
lipid adjuvants TDB and TDM mediate their protective eff  ects 
via Syk  –  Card9 signaling provides a rational basis for the fur-
ther development of effi   cient TB immunization strategies. 
    MATERIALS AND METHODS   
  Mice.     C57BL/6 mice were purchased from Harlan-Winkelmann. Breeding 
pairs for mice defi  cient in Myd88 were provided by S. Akira (Research Insti-
tute for Microbial Diseases, Osaka, Japan). Card9      /     , Bcl10      /     , and Malt1      /      
mice have been previously described (  4, 19  ). All knockout mice used for im-
munization experiments were backcrossed to C57BL/6 for at least six genera-
tions. Syk  +/      mice were provided by V. Tybulewicz (National Institute for 
Medical Research, London, England, UK). Syk      /      and Syk  +/+   fetal liver cells 
were used to generate BM radiation chimeras. Dap12      /      and Fcer1g      /      mice 
were used with permission from T. Takai (  26, 27  ). Dectin1      /      mice have 
been previously described (  28  ). Animal experiments were approved by the 
Regierung von Oberbayern (AZ209.1/211-2531-33/05) and the Animal 
Research Ethics Board of the Ministry of Environment, Nature Protection 
and Agriculture, Kiel, Germany. 
  Reagents.     CpG ODN 1826 has been previously described (  21  ) and was sup-
plied in phosphorothioate form by Coley Pharmaceuticals.   E. coli   O55:B5 LPS 
was obtained from Sigma-Aldrich. TDB was purchased from Sigma-Aldrich or 
Avanti Polar Lipids. TDM was purchased from Sigma-Aldrich or Axxora. The 
purity of TDB and TDM was confi  rmed by mass spectrometry. For prepara-
tion of liposomes, dimethyldioctadecylammonium (DDA) bromide and TDB 
were purchased from Avanti Polar Lipids. The fusion protein of Ag85B and 
ESAT-6 (designated H1) was produced as a recombinant protein, as previously 
described (  29  ). Piceatannol (Calbiochem) was solubilized in DMSO. Curdlan 
was purchased from Wako Chemicals. IFN-     was purchased from Tebu-Bio. 
this innate pathway is responsible for the adjuvant activity of 
TDB in vivo, we immunized Card9      /      animals with H1 and 
TDB or TDM. Card9-defi  cient mice were used as they have 
selective defects in myeloid cells but intact lymphocyte acti-
vation, in contrast to Syk      /     , Bcl10      /     , and Malt1      /      ani-
mals (  4, 19  ). Although the transient footpad swelling after 
injection of H1 in liposomes alone was comparable between 
wild-type and Card9      /      mice, the inclusion of TDB (  Fig. 4 A  ) 
or TDM (not depicted) into the liposomes caused an increase 
in footpad thickness that was completely abrogated in Card9-
defi  cient mice.   Moreover, TDB and TDM injection aug-
mented draining lymph node cellularity in wild-type but not 
Card9      /      mice, whereas the response to CpG was compara-
ble between the two genotypes (  Fig. 4 B  ). The TDM- or 
TDB-induced capacity of lymph node cells for IFN-     pro-
duction was reduced in Card9      /      mice, indicating that Th-1 
diff  erentiation directed by these glycolipids depends on Card9 
(  Fig. 4 C  ). The development of a H1-specifi  c IL-17 produc-
tion conferred by TDB and TDM was completely abrogated, 
suggesting a crucial role of the Syk  –  Card9 pathway for TDB-/
TDM-induced Th-17 diff  erentiation (  Fig. 4 C  ). Moreover, 
H1-specifi  c IgG2a antibody levels were Card9 dependently 
enhanced by TDB (  Fig. 4 D  ). Thus, using diff  erent readout 
systems for Th-1, Th-17, and antibody responses, we fi  nd 
that Card9 is essential to mediate the adjuvanticity of TDB 
and TDM in vivo. 
  To test whether Card9 signaling is also responsible for the 
immune protection after subunit vaccination with H1 plus 
TDB, which confers a similar reduction in pulmonary myco-
bacterial load as the live BCG vaccine (  13  ), we challenged im-
munized mice with low-dose aerosol MTB infection and 
analyzed CFUs in the organs 6 wk later. As expected, com-
pared with naive mice, vaccination with H1 in TDB-contain-
ing liposomes caused a signifi  cant reduction of mycobacterial 
load in the lungs of wild-type mice, whereas the liposomes 
alone had no signifi  cant eff  ect (  Fig. 4 E  ). In sharp contrast, im-
munization with TDB and H1 failed to reduce the number of 
mycobacterial CFUs in the lungs of Card9      /      mice, demon-
strating a key role of Card9-signaling in TDB-induced protec-
tive immunity against tuberculosis in vivo. This protective 
eff  ect correlated with the Card9-dependent induction of anti-
gen-specifi  c Th-17 cells in the mediastinal lymph nodes after 
vaccination, but not with the frequency of H1-specifi  c IFN-      –
  producing CD4  +   T cells (  Fig. 4 F  ). Notably, lung mycobacte-
rial load in nonimmunized Card9      /      mice was higher than in 
wild types (P   <   0.01), suggesting an additional role for the 
Card9 pathway in the natural resistance to MTB infection that 
deserves further detailed investigation and that could explain 
the substantially elevated numbers of IFN-      –  producing T cells 
in Card9      /      mice (  Fig. 4 F  ). 
  Concluding remarks 
  In conclusion, we report the molecular pathway for the adju-
vanticity of TDM and TDB by demonstrating that these gly-
colipids specifi  cally activate APCs via Syk  –  Card9  –  Bcl10  –  Malt1 
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nized with 2   μ  g of the vaccine antigen H1 emulsifi  ed in 100   μ  l of each adju-
vant (50   μ  l per foot), comprising either 250   μ  g DDA liposomes alone, 250   μ  g 
DDA + 50   μ  g TDB, or 250   μ  g DDA + 50   μ  g TDM. DDA was suspended in 
sterile distilled water at 2.5 mg/ml, heated to 80  °  C for 20 min with continu-
ous stirring in order for liposomes to form, and left to cool at room tempera-
ture. A stable formulation of DDA/TDB was prepared by the lipid fi  lm 
hydration method, as previously described (  12  ). TDM was suspended in ster-
ile distilled water containing 2% dimethylsulfoxide to a concentration of 
5 mg/ml by repeated passaging through a fi  ne-tipped pipette, followed by 
vortexing. This step was repeated 3 times before freezing the solution at     20  °  C 
until use. Before immunization, H1 was mixed in Tris buff  er and TDM was 
added and fi  nally mixed with DDA. For immunization with CpG as adju-
vant, H1 was mixed in PBS with the ODN such that one dose (per footpad) 
contained 2   μ  g H1 protein and 5 nmol CpG. 
  Footpad thickness was determined with a caliper before and at several 
time points after injection. Baseline values were subtracted individually for 
both feet of each mouse. 
  Measurement of antigen-specifi  c production of IFN-     and IL-17.     
4 wk after the fi  rst immunization, the draining lymph nodes of the mice were 
removed and passed through a 100-  μ  m nylon cell strainer (BD). For restimula-
tion, 3   ×   10  5   cells (in a total volume of 250   μ  l RPMI) were plated in triplicate 
in 96-well culture plates. H1 antigen was used at 1   μ  g/ml and 10   μ  g/ml fi  nal 
concentrations for restimulation. Wells containing medium only or 1   μ  g/ml 
ConA were used as negative and positive controls, respectively. Culture super-
natants were harvested after 96 h incubation, and the amount of IFN-     and 
IL-17 was determined by ELISA. 
  Determination of antigen-specifi  c antibody responses.     To evaluate the 
presence of H1-specifi  c antibodies, mouse sera of the immunized mice were 
analyzed in triplicate in threefold dilutions (beginning at a 1/1,000 dilution). 
Reagents used for determining specifi  c antibody titers were rabbit anti  –  mouse 
IgG1 and IgG2a  b   (BD). Absorbance was read on an ELISA reader at 450 nm. 
  Low-dose aerosol MTB challenge.     Before infection of experimental ani-
mals, stock solutions of MTB H37rv were diluted in sterile distilled water and 
pulmonary infection with 100 CFU/lung was performed using an inhalation 
exposure system (Glas-Col). 6 wk after infection, mice were sacrifi  ed to asepti-
cally remove lungs and mediastinal lymph nodes. To determine bacterial loads, 
lungs were weighed and homogenized in PBS containing a proteinase inhibi-
tor cocktail (Roche). 10-fold serial dilutions of organ homogenates were plated 
in duplicates onto Middlebrook 7H10 agar plates containing 10% OADC and 
incubated at 37  °  C for 19  –  21 d. Colonies on plates were enumerated and results 
expressed as log  10   CFU per organ. To analyze the frequency of Th-1 and -17 
cells, CD4 T cells from mediastinal lymph nodes were enriched by magnetic 
cells sorting (Miltenyi). Detection of antigen-specifi  c IFN-      –   and IL-17  –  pro-
ducing CD4 T cells was conducted using ELISPOT assay kits from BD and 
R  &  D Systems, respectively. Doubling dilutions of CD4 T cells were incubated 
with mitomycin-D  –  inactivated (Sigma-Aldrich) splenocytes from uninfected 
wild-type mice and were restimulated with H1 at a concentration of 10   μ  g/ml 
in the presence of 10 U/ml recombinant mouse IL-2 (Peprotech). After devel-
opment, spots were automatically enumerated using an ELISPOT reader 
(ELISpot 04 XL; AID Diagnostika), and the frequency of responding CD4 
T cells was determined. 
  Online supplemental material.     Fig. S1 gives the chemical structures of TDB 
and TDM. Fig. S2 depicts validation of microarray data. Fig. S3 shows produc-
tion of TNF-     and NO by DCs in response to TDB and TDM. Myd88-inde-
pendent expression and secretion of IL-6 by TDB-stimulated macrophages is 
shown in Fig. S4. Fig. S5 shows IL-6 and -1b ELISA data from Syk-defi  cient 
macrophages. Inhibition of TDB- and TDM-induced NO release by Piceatannol 
is depicted in Fig. S6. Fig. S7 depicts Card9-dependent NO production by mac-
rophages. Fig. S8 shows the expression of cytokines in DCs in response to TDB. 
Fig. S9 is a NF-    B EMSA showing Card9-dependent activation in DCs. Fig. S10 
gives qPCR data showing Dectin1-independent expression of iNOS, IL-1    , and 
  Generation of macrophages and dendritic cells.     Macrophages were 
diff  erentiated from BM cells in cDMEM containing 10% L-cell conditioned 
medium for 6  –  7 d. After removal of nonadherent cells, macrophages were 
detached from Petri dishes using Accutase treatment, washed, counted, and 
replated at a density of 10  6   cells/ml. Macrophages were rested overnight be-
fore stimulation, as indicated in the fi  gure legends. Where indicated, cells 
were pretreated for 3 h with IFN-     at a concentration of 10 ng/ml. For gen-
eration of BMDC, BM cells were cultured on Petri dishes for 7 d in cRPMI 
containing 20 ng/ml of GM-CSF (Peprotech). The cells were plated at a 
density of 5   ×   10  5   cells/ml and stimulated as indicated in the fi  gure legends. 
  Stimulation of macrophages with TDB and TDM.     Stocks of the glyco-
lipids TDB and TDM were prepared by solubilizing in PBS with 2% DMSO 
by alternating vortexing and heating to 50  °  C at a concentration of 2.5 mg/ml. 
Macrophages were stimulated using 1  –  50   μ  g/ml TDB or TDM as indicated in 
fi  gure legends. In some experiments, the glycolipids were coated directly to 
the bottom of cell culture plates after the procedure described by Ozeki et al. 
(  30  ). In brief, 2.5 mg/ml TDB or 1 mg/ml TDM were dissolved in isopropa-
nol by heating to 60  °  C for 20 min, followed by vortexing for 5 min. The gly-
colipids were coated in a volume of 20   μ  l for 96-well plates and 40   μ  l for 
48-well plates. Concentrations were calculated by dividing the amount of 
TDB/TDM in the wells by the culture medium volume. 
  Measurement of NO and cytokines.     The Griess assay was used to deter-
mine the reaction products of NO in culture supernatants of stimulated macro-
phages. Levels of cytokines were measured by sandwich ELISA using antibody 
pairs from R  &  D Systems. 
  RNA isolation.     Total RNA was prepared from stimulated macrophages us-
ing RNeasy Mini kit (QIAGEN) and measured on a Nanodrop spectropho-
tometer. RNA samples used for microarray analysis were quality controlled for 
integrity of the RNA using Bio-Rad Experion Standard Sensitivity Chips 
(Bio-Rad Laboratories). 
  Microarray analysis.     Aff   ymetrix GeneChips were used for genome-wide 
transcriptome analysis of 1   μ  g total RNA per sample, following the manufactur-
er  ’  s instruction for labeling and hybridization of the samples. In the fi  rst experi-
ment measuring the kinetics of changes induced by CpG or TDB in   Fig. 1  , 
samples were processed using the GeneChip Expression 3     Amplifi  cation One-
Cycle Target Labeling kit. Biotinylated cRNA was then hybridized on MOE430 
2.0 GeneChips that were stained, washed, and scanned after standard procedures. 
In the second experiment, comparing wild-type and Card9      /      macrophages af-
ter a 48-h stimulation with CpG, Curdlan, and TDB (  Fig. 3  ), samples were pro-
cessed with the Whole Transcript Assay kit and hybridized to Mouse Gene 1.0 
ST GeneChips, as detailed by the manufacturer. CEL fi  les were processed for 
global normalization and generation of expression values using the robust multi-
array average algorithm. To select regulated genes, the data were fi  ltered by ex-
cluding all probe sets that over all conditions showed  <  10-fold ( Fig. 1 ) or  <  5-fold 
(  Fig. 3  ) change and an absolute diff  erence between maximum and minimum 
expression values of   <  200 (  Fig. 1  ) or   <  100 (  Fig. 3  ). The probe sets passing these 
criteria were z-score normalized and subjected to hierarchical clustering using 
Spotfi  re DecisionSite Functional Genomics software. Tables S1 and S2 (available 
at http://www.jem.org/cgi/content/full/jem.20081445/DC1) list the expres-
sion data for the probe sets shown in   Fig. 1 D   and   Fig. 3 D  , respectively. The 
Cel fi  les for both experiments were submitted to the public repository Gene Ex-
pression Omnibus (Accession nos.   GSE10530   and   GSE10532  ). 
  Quantitative RT-PCR.     Expression levels of the housekeeping gene 
HPRT, the cytokines IL-6 and -1    , and iNOS were analyzed using primer/
probe combinations selected from the Roche Universal Probe Library and 
are available upon request. Fold changes were calculated with the         CT 
method using the untreated sample as a calibrator. 
  Immunization of mice with Ag85B  –  ESAT-6 fusion protein H1.   
  Groups of 3  –  6 mice were immunized subcutaneously by footpad injection 
2 or 3 times, with a 2-wk interval between injections. All mice were immu-JEM VOL. 206, January 19, 2009  97
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